MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis

Hamed Alborzinia(German Cancer Research Center), Andrés F. Flórez(Harvard University), Sina Kreth(German Cancer Research Center), Lena Brückner(German Cancer Research Center), Umut Yildiz(German Cancer Research Center), Moritz Gartlgruber(German Cancer Research Center), Dorett I. Odoni(University of Augsburg), Gernot Poschet(Heidelberg University), Karolina Garbowicz(German Cancer Research Center), Chunxuan Shao(German Cancer Research Center), Corinna Klein(German Cancer Research Center), Jasmin Meier(German Cancer Research Center), Petra Zeisberger(German Cancer Research Center), Michal Nadler-Holly(Max Delbrück Center), Matthias Ziehm(Max Delbrück Center), Franziska Paul(Weizmann Institute of Science), Jürgen Burhenne(Heidelberg University), Emma Bell(German Cancer Research Center), Marjan Shaikhkarami(Heidelberg University), Roberto Würth(German Cancer Research Center), Sabine Stainczyk(German Cancer Research Center), Elisa M. Wecht(German Cancer Research Center), Jochen Kreth(German Cancer Research Center), Michael Büttner(Heidelberg University), Naveed Ishaque(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Matthias Schlesner(University of Augsburg), Barbara Nicke(Target (Germany)), Carlo Stresemann(Bayer (Germany)), Maria Llamazares Prada(German Cancer Research Center), Jan H. Reiling(The University of Texas MD Anderson Cancer Center), Matthias Fischer(University of Cologne), Ido Amit(Weizmann Institute of Science), Matthias Selbach(Max Delbrück Center), Carl Herrmann(German Cancer Research Center), Stefan Wölfl(Heidelberg University), Kai‐Oliver Henrich(German Cancer Research Center), Thomas Höfer(German Cancer Research Center), Andreas Trumpp(German Cancer Research Center), Frank Westermann(German Cancer Research Center)
Nature Cancer
April 28, 2022
Cited by 223Open Access
Full Text

Abstract

Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces massive lipid peroxidation on depletion of cysteine, the rate-limiting amino acid for glutathione (GSH) biosynthesis, and sensitizes cells to ferroptosis, an oxidative, non-apoptotic and iron-dependent type of cell death. The high cysteine demand of MYCN-amplified childhood neuroblastoma is met by uptake and transsulfuration. When uptake is limited, cysteine usage for protein synthesis is maintained at the expense of GSH triggering ferroptosis and potentially contributing to spontaneous tumor regression in low-risk neuroblastomas. Pharmacological inhibition of both cystine uptake and transsulfuration combined with GPX4 inactivation resulted in tumor remission in an orthotopic MYCN-amplified neuroblastoma model. These findings provide a proof of concept of combining multiple ferroptosis targets as a promising therapeutic strategy for aggressive MYCN-amplified tumors.


Related Papers

No related papers found

Powered by citation graph analysis